Cell line authentication provides a serious solution to the problem of irreproducibility in clinical trials. So then why isn’t it being widely implemented? GEN discusses.
ADME/Tox activities play a key role in improving early-stage drug screening. Charles River’s Steven Bulera discusses some of best emerging practices in toxicology in GEN.
New strategies and methodologies in contemporary assay development include the creation of 3D models that more accurately capture cellular microenvironments; the use of primary cells to accomplish phenotypic modeling; the engineering of responsive, division-arrested cells; and the targeting of specific cellular pathways.
Charles River Laboratories brought in three new discovery contracts with outfits funded by the Wellcome Trust, lending its expertise in early-stage drug development.
Few of us would ever get a vaccination or unseal a bottle of contact solution if we thought it was contaminated, so responsible manufacturers devote considerable resources making sure bacteria and fungi don’t end up in the supply chain.
Contract Pharma discusses the strategy behind the acquisition of Celsis International and the increasingly important area of quality control testing with Foster T. Jordan, corporate senior vice president, endotoxin and microbial detection, Charles River Laboratories.
In this interview, James Foster, chairman and CEO of Charles River Laboratories, discusses the reopening of the Shrewsbury, Massachusetts facility and Charles River’s partnership with AstraZeneca.
Charles River has announced a $212 million purchase of British company Celsis International. The company specializes in providing systems that are used to detect harmful contaminants in substances ranging from prescription drugs to consumer beverages.
The acquisition of Celsis International Ltd. complements Charles River Endotoxin and Microbial Detection’s (EMD) position as a leading provider of rapid endotoxin testing and bacterial identification for biopharmaceutical manufacturing, and creates the most comprehensive solution for rapid quality control testing of biopharmaceutical and consumer products.
Charles River announced that it has entered into a definitive agreement to acquire Celsis International Ltd. for $212 million in cash, subject to customary closing adjustments.